Cerebrolysin – Brain Regeneration Treatment
Cerebrolysin is a multi-modal neuropeptide drug with a fast onset of action that helps to regain and maintain the independence of patients suffering from stroke, Traumatic brain injury (TBI), dementia and cognitive impairment. It is produced by standardized enzymatic breakdown of lipid-free porcine brain proteins
It acts similar to neurotrophic factors that already exist in your system in the form of promoting neuronal sprouting, stimulating neurogenesis, enhancing neuronal plasticity, and improving learning and memory.
Several studies demonstrated that Cerebrolysin can be used safely in the management of children with any of the following medical conditions: minimal cerebral dysfunction, resistant forms of nocturnal enuresis, neurosensory hypoacusis, attention deficit hyperkinetic disorder, autism and Asperger syndrome.
Cerebrolysin improves the brain’s ability for self-repair by stimulating neuro recovery. Cerebrolysin is clinically proven by the European, Austrian, Mexican and Russian Health boards.
Cerebrolysin – Brain Regeneration Treatment Protocol
At Dream Body Clinic we typically administer at least 1 vial of 10ml via an infusion IV. This dose can be up to 50ml depending on the patients ailment.
We typically send patients home with 2 boxes of cerebrolysin so that they can do a 20 day cycle of intramuscular injections at 5ml per day. 2 boxes costs $600 usd total. This protocol changes depending on the patient and their needs. Fortunately it is the patients right to seek medical treatment abroad and return home with up to 50 dose units of medication. This allows us to send patients home with enough cerebrolysin to do multiple cycles.
Cerebrolysin for Alzheimer’s / Dementia
All pharmacological attempts to treat dementia aim to preserve and improve cognitive function and to delay progression to the later stages of the disease. Appropriate management of the disease by currently available drugs aim to stabilize the condition for a certain period, to improve cognition, to reduce behavioral disturbances and thus to delay the need for institutionalization.In spite of enormous efforts in academic and industrial research, there has still been no major breakthrough in therapies for neurodegenerative diseases.